GlassScriptPhysician profile
Tracy S Darlington
NPI 1518384569
$5,972.40
in general payments reported to CMS, 2019-2025
48 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $1,192 · 2023: $903 · 2024: $1,429 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,084 · Education: $108 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.53 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.30 |
| Education | $107.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.53 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.28 | 2021-2025 | |
| Ucb, INC. | $412.56 | 2023-2025 | Zilbrysq, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $293.62 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $281.12 | 2021-2025 | Crexont, Rytary |
| Pfizer INC. | $280.73 | 2023-2025 | |
| Lilly USA, LLC | $271.87 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Sk Life Science, INC. | $249.58 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $231.31 | 2021-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $223.18 | 2021-2025 | Ajovy, Austedo Xr |
| Neurelis, INC. | $221.93 | 2021-2025 | Valtoco |
| Kyowa Kirin, INC. | $202.74 | 2021-2024 | Nourianz |
| Mdd US Operations, LLC | $189.43 | 2023-2025 | Gocovri, Gocovri, Apokyn |
| Biogen, INC. | $155.00 | 2024-2025 | Vumerity, Leqembi |
| Neurocrine Biosciences, INC. | $137.25 | 2022-2025 | Ingrezza, Ongentys |
| E.R. Squibb & Sons, L.L.C. | $116.75 | 2024 | Zeposia |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $114.67 | 2021-2025 | Nuplazid |
| Impel Pharmaceuticals INC. | $107.83 | 2023 | Trudhesa |
| Celgene Corporation | $93.88 | 2025 | Zeposia |
| Argenx US, INC. | $83.98 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Medtronic, INC. | $83.11 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Jazz Pharmaceuticals INC. | $81.97 | 2023-2025 | |
| Amgen INC. | $77.80 | 2022-2025 | Aimovig, Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $71.92 | 2022 | |
| Collegium Pharmaceutical, INC. | $49.27 | 2022 | |
| Averitas Pharma INC. | $49.09 | 2025 | Qutenza |
| Genzyme Corporation | $41.88 | 2022-2025 | |
| Eisai INC. | $41.06 | 2025 | |
| Livanova USA, INC. | $39.42 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Boston Scientific Corporation | $31.66 | 2022-2025 | Watchman Access System |
| Vanda Pharmaceuticals INC. | $30.61 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $26.93 | 2025 | Xeomin |
| Corium, LLC | $26.76 | 2023 | Adlarity |
| Lundbeck LLC | $25.90 | 2025 | Rexulti |
| Grifols USA, LLC | $23.41 | 2022 | |
| Cala Health, INC. | $22.93 | 2022 | |
| Tg Therapeutics, INC. | $22.46 | 2025 | |
| Sanofi-Aventis U.S. LLC | $20.14 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.93 | 2025 | |
| Axsome Therapeutics, INC. | $16.59 | 2025 | Symbravo |
| Insightec,INC | $16.43 | 2025 | Exablate |
| Idorsia Pharmaceuticals US INC | $16.28 | 2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $14.85 | 2025 | Horizant |
| Tanabe Pharma America, INC. | $13.64 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $13.44 | 2024 | |
| Upsher-Smith Laboratories LLC | $12.59 | 2021 | |
| Alfasigma USA, INC. | $12.39 | 2021 | |
| Sumitomo Pharma America, INC. | $11.70 | 2023 | Aptiom |
| Supernus Pharmaceuticals, INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Darlington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.